National Center for Advancing Translational Sciences (NCATS/NIH)

6 articles about National Center for Advancing Translational Sciences (NCATS/NIH)

• Beactica Therapeutics announces collaboration with the National Center for Advancing Translational Sciences

  9/26/2023

  Beactica Therapeutics AB, the Swedish precision oncology company, announced that it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences, one of 27 institutes and centers at the U.S. National Institutes of Health.

• AllStripes Announces Collaboration with NIH’s NCATS to Launch Effort in Rare Disease Diagnosis

  4/27/2021

  AllStripes, a healthcare technology company dedicated to accelerating treatment research for patients with rare diseases, announced a collaboration with the National Center for Advancing Translational Sciences, an institute of the NIH established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster.

• NRL, NCATS Scientists Develop Method to Safely Study COVID-19, Other Contagious Diseases

  9/17/2020

  Scientists and researchers at the U.S. Naval Research Laboratory and National Center for Advancing Translational Sciences submitted their findings to ACS Nano, a monthly peer-reviewed scientific journal, on their collaboration to develop SARS-CoV-2 nanoparticle probes that are used to study fundamental interactions between SARS-CoV-2 Spike proteins and human cells.

• Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health

  5/11/2020

  Targeting Q3 2020 initiation of an adaptive Phase 2/3 trial evaluating emetine in high-risk COVID-19 outpatients, following IND submission and clearance

• Kebotix, NCATS Collaborate to Deliver New Treatments for Diseases Faster

  2/12/2020

  Feb. 12, 2020 14:00 UTC Advancement Aimed at Bridging Gap between Automation and Autonomy CAMBRIDGE, Mass.--( BUSINESS WIRE )-- For the National Center for Advancing Translational Sciences ( NCATS ), it’s all about delivering new treatments and cures for diseases faster. “If you ask a patient when they want their cure, they’ll say yesterday,” said Sam Michael, NCATS chief information officer. “Generating a new therapeutic can take 10 to 15 years and billions of dollars

• AnaBios Wins NCATS ASPIRE Award to Further Develop Preclinical Pain Assays Using Human Sensory Neurons

  9/26/2019

  The National Center for Advancing Translational Sciences awarded AnaBios the ASPIRE Design Challenge award in the category entitled, "Biological Assays for Translational Innovation in Pain, Opioid Use Disorder and Overdose." Funds from the award will be used to study ex vivo human models of pain for translational drug discovery.